Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD

Tripepi, Giovanni; Kollerits, Barbara; Leonardis, Daniela; Yilmaz, Mahamut Ilker; Postorino, Maurizio; Fliser, Danilo; Mallamaci, Francesca; Kronenberg, Florian; Zoccali, Carmine

doi:10.1681/asn.2013121355

Cited by 24 publications

(30 citation statements)

References 49 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight cohort studies ( n = 10,075) [26-28, 30, 33-36] investigated the association between FGF23 and all-cause mortality risk, and 8 studies ( n = 8,013) [23, 26-28, 30, 31, 35, 37] assessed the association between FGF23 and CVD risk. Eight studies ( n = 9,524) [24,25,29,30,32,[34][35][36] assessed the association between FGF23 and renal events risk. The duration of follow-up ranged from one year to 10.5 years [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] .…”

Section: Study Characteristicsmentioning

confidence: 99%

Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease

et al. 2016

View full text Add to dashboard Cite

Background: Quantitative dose-response associations between fibroblast growth factor 23 (FGF23) and risks of mortality, cardiovascular disease (CVD), and renal events in chronic kidney disease (CKD) are not known. This study aimed to summarize and quantify the predictive effects of FGF23 among the pre-dialysis CKD stages 1-5 population. Methods: Data sources included PubMed, EMBASE, and Web of Science. Prospective cohort studies assessing the associations between FGF23 and all-cause mortality, CVD, and renal events in CKD patients were selected. Summary risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using the random-effects model. The composite higher or the highest level in FGF23 categories of each study was considered the high level. The reference level was regarded as the low level in the overall analysis. The restricted cubic spline model was used to estimate dose-response associations. Results: Fifteen prospective cohort studies centered around 15,355 subjects were analyzed. A high FGF23 level was associated with increased risks of all-cause mortality (RR 1.46, 95% CI 1.38-1.55, p < 0.001), CVD (RR 1.37, 95% CI 1.15-1.63, p < 0.001), and renal events (RR 1.31, 95% CI 1.07-1.59, p = 0.008), respectively. There was a positive, nonlinear, dose-response relationship between FGF23 and all-cause mortality. The reference level in dose-response analysis was defined as 51 RU/mL of c-terminal FGF23. We then calculated RRs for increments of 20 RU/mL, which was associated with increased risks of mortality (RR 1.04, 95% CI 1.00-1.07, p = 0.038), CVD (RR 1.02, p < 0.001), and renal events (RR 1.01, p < 0.001), respectively. Conclusions: There may be positive dose-response predictive effects of FGF23 on all-cause mortality, CVD, and renal events in patients with CKD.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…and ADMA levels in terms of the renal and cardiovascular outcomes [15]. The increase in both markers after TRT may be an early indicator of adverse cardiovascular events in CHH.…”

Section: Prace Oryginalnementioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

“…FGF-23 also plays role in the pathogenesis of endothelial dysfunction and atherosclerosis [13][14][15]. There is a competitive interaction between the levels of FGF 23 and asymmetric dimethylarginine (ADMA), a well-documented surrogate for endothelial dysfunction [15]. Despite the significant impairment of endothelial functions and bone mineral metabolism in hypogonadism, little is known about the levels of FGF-23 and the role it plays in these patients [16,17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Wpływ testosteronowej terapii zastępczej na stężenia witaminy D i FGF-23 w hipogonadyzmie wrodzonym

Haymana¹,

Sönmez²,

Aydoğdu³

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Patients with hypogonadism are at increased risk of cardiac and metabolic diseases and osteoporosis. Vitamin D and fibroblast growth factor-23 (FGF-23) play a role in the regulation of bone mineral metabolism and endothelial functions. Low vitamin D levels are reported in hypogonadism, while there is no data about the effect of testosterone replacement therapy (TRT). We investigated the effect of TRT on vitamin D and FGF-23 levels along with endothelial functions and insulin resistance in hypogonadal patients. Material and methods:Patients with congenital hypogonadotrophic hypogonadism (CHH) (n = 32, age 20.6 ± 1.58 years) were enrolled. TRT was implemented in transdermal form. The demographic parameters, FGF-23, 25(OH)D3, asymmetric dimethylarginine (ADMA), and homeostatic model assessment of insulin resistance (HOMA-IR) levels, were measured both before and after TRT. Results: After a follow-up period of 3.63 ± 1.33 months, ADMA and FGF-23 levels were significantly increased (p = 0.03 and p = 0.005 respectively), while 25(OH)D3 and HOMA-IR index were not significantly changed. The body mass index and waist circumference levels of the patients were also increased (p < 0.001 and p = 0.02) along with a significant decrease in the HDL cholesterol levels (p = 0.006). Conclusions:The results show that short-term TRT increases plasma FGF-23 and ADMA levels but does not alter the vitamin D levels in young, treatment naive patients with CHH. Whether this is an early implication of TRT-related adverse effects in this very young and treatment naïve population of CHH is not clear. Future prospective studies are required to find out the long-term effects of TRT on cardiometabolic morbidity and mortality in this specific population. (Endokrynol Pol 2017; 68 (3): 311-316)

show abstract

“…52 Recent studies in patients with chronic kidney disease (CKD) suggest that there is a relationship or association between ADMA levels and fibroblast growth factor 23 (FGF-23), and also a relationship with markers of endothelial cell damage. 53,54 Several different studies have assessed conventional and innovative biomarkers for prediction of cardiovascular events. Reriani et al 55 point out that there is a need to evaluate the utility of putative biomarkers for evaluation of cardiovascular risk, when compared with endothelial function, because of the small additional value offered by these biomarkers when compared with conventional risk factors.…”

mentioning

confidence: 99%

Biomarcadores de função endotelial em doenças cardiovasculares: hipertensão

Neves

Oliveira

2016

J. vasc. bras.

View full text Add to dashboard Cite

The incidence of systemic arterial hypertension is increasing worldwide. The foundation of prevention is identification of people with hypertension. Nowadays, biomarkers are used to diagnose and stratify diseases and estimates prognosis. The objective of this study was to review articles published over the last 5 years on the subject of biomarkers of cardiovascular diseases. The PubMed, SciELO, Science Direct and MEDLINE databases were searched using the keywords: arterial hypertension, cardiovascular biomarkers, nitric oxide, endothelial function and asymmetric dimethylarginine. The studies reviewed show that cardiovascular diseases have complex etiologies. This article describes evidence demonstrating interactions between nitric oxide and asymmetric dimethylarginine that are involved in regulation, in metabolism, and in determination of intracellular levels, and also discusses other biomarkers related to hypertension. Some studies indicate that biomarkers are useful tools for prediction of cardiac events, whereas others state that they have little to contribute to assessments. Careful selection of tests and combinations of tests may be the key to validating use of biomarkers, in view of their low specificity for diagnosing hypertension.Keywords: biomarkers; hypertension; endothelial function; ADMA. ResumoA incidência de hipertensão arterial sistêmica está aumentando mundialmente. Sua prevenção baseia-se na identificação dos hipertensos. Atualmente, biomarcadores são utilizados com fins de diagnosticar, estratificar e prognosticar doenças. Neste estudo, objetivou-se revisar artigos dos últimos cinco anos relacionados a biomarcadores nas doenças cardiovasculares. Pesquisaram-se dados de PubMed, SciELO, Science Direct e MEDLINE, mediante as palavras-chave: hipertensão arterial, biomarcadores cardiovasculares, óxido nítrico, função endotelial e dimetilarginina assimétrica. Os estudos levantados mostram que as doenças cardiovasculares possuem uma etiologia complexa. Neste artigo, evidenciaram-se interações entre o óxido nítrico e a dimetilarginina assimétrica na regulação, no metabolismo e na determinação dos níveis intracelulares, e reviram-se outros biomarcadores relacionados à hipertensão. Alguns estudos indicam os biomarcadores como uma ferramenta útil na predição de eventos cardíacos, e outros reportam que eles contribuem pouco para a avaliação. A seleção e combinação desses pode ser uma alternativa para validar o uso dos biomarcadores devido à pouca especificidade existente para diagnosticar a hipertensão. Palavras

show abstract

Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD

Cited by 24 publications

References 49 publications

Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease

Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease

Wpływ testosteronowej terapii zastępczej na stężenia witaminy D i FGF-23 w hipogonadyzmie wrodzonym

Biomarcadores de função endotelial em doenças cardiovasculares: hipertensão

Contact Info

Product

Resources

About